2 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
| Phase 2 | 1 | Unknown 1 |
Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. sepofarsen - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Unknown | ProQR Therapeutics | 15 | 2021-03-23 | 2022-03-25 |
| Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception tasimelteon - Non 24 Hour Sleep Wake Disorder | Phase 3 | Unknown | Vanda Pharmaceuticals | 140 | 2010-10-28 | 2024-04-03 |
Eye Diseases (2) · Chronobiology Disorders (1) · Dyssomnias (1) · Eye Abnormalities (1) · Leber Congenital Amaurosis (1) · Leber Congenital Amaurosis 10 (1) · Meckel Syndrome, Type 4 (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Retinal Dystrophies (1) · Sensation Disorders (1) · Sleep Disorders, Circadian Rhythm (1)
Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Eye Diseases, Hereditary (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Occupational Diseases (1) · Sensation Disorders (1) · Vision Disorders (1)
tasimelteon (1)
ProQR Therapeutics (1) · Vanda Pharmaceuticals (1)
Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · United Kingdom (1)